Cdh5(PAC)-CreERT2 Mouse

Random Transgenic

Cdh5(PAC)-CreERT2 Random Transgenic Mouse Model

C57BL/6 Background

  • Model #
  • Genotype
  • Nomenclature
  • 13073-F
    tg/wt
    B6.CBA-Tg(Cdh5-cre/ERT2)1Rha
  • 13073-M
    tg/wt
    B6.CBA-Tg(Cdh5-cre/ERT2)1Rha
  • An inducible cre deleter under the control of the vascular endothelial cadherin (Cdh5(PAC)) promoter
  • Cre recombination is inducible via administration of tamoxifen
  • Useful for study of angiogenesis, atherosclerosis and neovascularization
  • Non-induced Cdh5(PAC)-CreERT2 mice demonstrate no Cre recombinase activity, while tamoxifen-induced Cdh5(PAC)-CreERT2 mice demonstrate high levels of recombinase-mediated gene deletion in vascular endothelial cells (95%+).
Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Origin:

The Cdh5(PAC)-CreERT2 Mouse was developed in the laboratory of Ralf Adams at the London Research Institute. The model was generated by microinjecting a transgene containing a genomic Cdh5(PAC) promoter fragment fused to a CreERT2 cDNA into B6xCBA F1 zygotes. Founder lines were backcrossed to C57BL/6 for at least five generations. Taconic received embryos from CRT in 2013.

Source:

Sponsor: Cancer Research Technology

Availability:

Limited quantities of breeders are available for purchase after execution of a license.

Ordering Note: Animals ordered at 4 weeks of age require rapid genotyping and a $40.00 per mouse charge will be added.

Color:

Black

Species:

Mouse

Initial Publication:

Sörensen I, Adams RH, Gossler A. (2009) DLL1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. Blood. 113(22):5680-8.


Conditions of Use for Taconic Transgenic Models™
Taconic Transgenic Models™ (Models) are produced and distributed under rights to patents and intellectual property licensed from various institutions. Taconic sells the Models to purchasers, grants to each purchaser a right under Taconic's rights in such licensed patents and intellectual property to use the purchased Model in consideration of purchasers' acknowledgement of and agreement to the Terms and Conditions of Sale and the following terms of use:
  • Access to this model requires execution of a Limited Breeding Agreement.
  • Purchase of line #13073 includes the right under the patents owned by Le Centre Européen de Recherche en Biologie et en Médecine ("CERBM") to perform inducible deletion (e.g. tamoxifen induction based deletion) using the CreER gene.
  • Title to these Models and biological materials derived from them remains with Taconic Biosciences, Inc.
  • The Models will be used for research purposes only.
  • The Models will not be bred or cross-bred except to obtain embryos or fetuses required for research purposes. This model may be eligible for a cross-breeding agreement. Please contact Taconic Customer Service for details.
  • The Models and biological materials derived from them will not be distributed to third parties or used for commercial purposes.
  • Non-profit purchasers may not use this Model and/or biological materials derived from it in sponsored research or contract research studies unless it is purchased at the for-profit price.
Conditions of Use - Printable Version